Online citations, reference lists, and bibliographies.
← Back to Search

Pathology Of Mesothelioma.

J. M. Corson
Published 2004 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
In this article, progress in distinguishing mesothelioma from mesothelial hyperplasia and fibrosing pleuritis was discussed. Advances in the immunohistochemical characterization of mesothelioma, in the recognition of entities that mimic mesothelioma, and in their distinction from mesothelioma were reviewed. Cytogenetic and molecular genetic contributions to the diagnosis of pleural synovial sarcoma were briefly summarized. The diagnosis of epithelial type mesothelioma can be established in most cases. Several mesotheliomas, however, especially rare subtypes, and sarcomatoid, desmoplastic, and poorly differentiated mesotheliomas continue to present diagnostic challenges.
This paper references
10.1046/j.1365-2559.2001.01295.x
Malignant epithelioid mesothelioma: anti‐mesothelial marker expression correlates with histological pattern
R. Attanoos (2001)
Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma.
K. Amin (1995)
10.1046/j.1365-2559.2002.01422.x
Primary thymic epithelial tumours of the pleura mimicking malignant mesothelioma
R. Attanoos (2002)
10.1093/AJCP/110.3.374
CD31 immunoreactivity in carcinomas and mesotheliomas.
B. R. De Young (1998)
10.1097/00000478-199609000-00001
Calretinin: a novel immunocytochemical marker for mesothelioma.
C. Doglioni (1996)
10.1093/AJCP/110.2.135
The diagnosis of desmoplastic malignant mesothelioma.
T. Colby (1998)
10.1002/1097-0142(19861001)58:7<1540::AID-CNCR2820580727>3.0.CO;2-5
Diffuse malignant mesothelioma of pleura: Diagnosis and survival in 92 cases
V. Adams (1986)
10.3109/01913128809064207
Lymphohistiocytoid mesothelioma: a rare lymphomatoid variant of predominantly sarcomatoid mesothelioma.
D. Henderson (1988)
10.1002/1097-0142(20011115)92:10<2727::AID-CNCR1627>3.0.CO;2-B
The value of cytokeratins 20 and 7 in discriminating metastatic adenocarcinomas from pleural mesotheliomas
T. Tot (2001)
10.1097/00000478-199202000-00006
Thymomas Presenting as Pleural Tumors: Report of Eight Cases
C. Moran (1992)
10.1097/00000478-200106000-00009
Primary Monophasic Synovial Sarcoma of the Pleura: Five Cases Confirmed by the Presence of SYT-SSX Fusion Transcript
M. Aubry (2001)
10.1309/7ECY-KN61-PP1M-52EB
Lymphohistiocytoid mesothelioma. An often misdiagnosed variant of sarcomatoid malignant mesothelioma.
H. Khalidi (2000)
10.1097/00000478-198908000-00003
Localized Benign and Malignant Fibrous Tumors of the Pleura: A Clinicopathologic Review of 223 Cases
D. England (1989)
10.1097/00000478-199807000-00008
Expression of bcl-2 oncoprotein in benign and malignant spindle cell tumors of soft tissue, skin, serosal surfaces, and gastrointestinal tract.
S. Suster (1998)
10.1046/j.1365-2559.1998.00565.x
Synovial sarcoma of the pleura and its differentiation from other primary pleural tumours: a clinicopathological and immunohistochemical review of three cases
Nicholson (1998)
10.3109/01913128709048446
Diffuse epithelial mesothelioma: a review of the ultrastructural spectrum.
I. Dardick (1987)
10.1097/00000478-198204000-00003
Desmoplastic diffuse mesothelioma
R. Cantin (1982)
10.1016/0046-8177(95)90254-6
Expression of muscle actins in diffuse mesotheliomas.
I. T. Kung (1995)
10.1097/00000478-199404000-00004
Localized Malignant Mesothelioma: A Clinicopathologic and Flow Cytometric Study
T. Crotty (1994)
10.1038/modpathol.3880018
Value of the Mesothelium-Associated Antibodies Thrombomodulin, Cytokeratin 5/6, Calretinin, and CD44H in Distinguishing Epithelioid Pleural Mesothelioma from Adenocarcinoma Metastatic to the Pleura
P. Cury (2000)
Pathology and genetics of tumours of soft tissue and bone
C. D. Fletcher (2002)
10.1016/S1010-7940(02)00735-2
The management of malignant pleural mesothelioma.
G. Maggi (2003)
10.1067/MTC.2002.124242
Synovial sarcoma of the pleura: a clinical and pathologic study of three cases.
A. Colwell (2002)
10.1097/00000478-198206000-00003
Malignant mesothelioma: Ultrastructural distinction from adenocarcinoma
Michael J. Warhol (1982)
10.1136/jcp.45.4.295
Desmoplastic malignant mesothelioma: a review of 17 cases.
G. Wilson (1992)
10.1002/cncr.10188
Primary pleuropulmonary synovial sarcoma
L. Essary (2002)
10.1007/978-3-642-41193-9_9
Cytopathology of Asbestos-Associated Diseases
F. Schneider (2004)
10.1002/(SICI)1096-9896(199701)181:1<67::AID-PATH723>3.0.CO;2-Z
WT1 MUTATION IN MALIGNANT MESOTHELIOMA AND WT1 IMMUNOREACTIVITY IN RELATION TO p53 AND GROWTH FACTOR RECEPTOR EXPRESSION, CELL‐TYPE TRANSITION, AND PROGNOSIS
S. Kumar-Singh (1997)
10.1097/00000478-200110000-00012
Well-Differentiated Papillary Mesothelioma
K. Butnor (2001)
10.1038/modpathol.3880483
Expression of Cytokeratin 5/6 in Epithelial Neoplasms: An Immunohistochemical Study of 509 Cases
P. Chu (2002)
10.1016/S0046-8177(00)80194-X
Malignant epithelioid vascular tumors of the pleura: report of a series and literature review.
P. Zhang (2000)
10.1002/1097-0142(19930715)72:2<394::AID-CNCR2820720214>3.0.CO;2-5
Thoracoscopy in pleural malignant mesothelioma: A prospective study of 188 consecutive patients. Part 2: Prognosis and staging
C. Boutin (1993)
10.1097/00000478-199712000-00002
The value of antibodies 44-3A6, SM3, HBME-1, and thrombomodulin in differentiating epithelial pleural mesothelioma from lung adenocarcinoma: a comparative study with other commonly used antibodies.
N. Ordóñez (1997)
10.1097/00000478-200004000-00016
Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma.
N. Ordóñez (2000)
10.1043/0003-9985(2003)127<85:PPS>2.0.CO;2
Primary pleural synovial sarcoma. A case report and review of the literature.
S. B. Ng (2003)
10.1016/S0046-8177(98)90006-5
Ultrastructural features of diffuse malignant mesotheliomas.
T. Oury (1998)
Molecular analyses, morphology and immunohistochemistry together differentiate pleural synovial sarcomas from mesotheliomas: clinical implications.
M. Carbone (2002)
10.1016/S0022-5223(99)70469-1
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
D. Sugarbaker (1999)
Histochemistry in the diagnosis of malignant mesothelioma.
M. Kannerstein (1973)
10.1093/AJCP/110.3.397
Reactive mesothelial hyperplasia vs mesothelioma, including mesothelioma in situ: a brief review.
D. Henderson (1998)
10.1046/j.1365-2559.1997.5460776.x
Pathology of malignant mesothelioma
R. Attanoos (1997)
The ultrastructural pathology of malignant pleural mesothelioma.
M. Coleman (1989)
10.1097/00000478-199712000-00003
The immunohistochemical diagnostic panel for epithelial mesothelioma: a reevaluation after heat-induced epitope retrieval.
J. R. Riera (1997)
10.1097/00125480-200007060-00001
Localized (Solitary) Fibrous Tumor of the Pleura
N. Ordóñez (2000)
10.1016/0046-8177(94)90243-7
Desmin and neural marker expression in mesothelial cells and mesotheliomas.
J. Hurlimann (1994)
Comprehensive textbook of thoracic oncology
J. Aisner (1996)
10.1002/1097-0142(19900115)65:2<292::AID-CNCR2820650218>3.0.CO;2-W
Well‐differentiated papillary mesothelioma of the peritoneum. A clinicopathologic study of 22 cases
D. Daya (1990)
10.1093/AJCP/112.1.43
Absence of SYT-SSX fusion products in soft tissue tumors other than synovial sarcoma.
M. van de Rijn (1999)
10.1309/315H-E2LY-QYE7-143J
Mesothelial proliferations. An increasing morphologic spectrum.
M. Wick (2000)
10.1043/0003-9985(2001)125<1316:IAONVC>2.0.CO;2
Immunohistochemical analysis of nuclear versus cytoplasmic staining of WT1 in malignant mesotheliomas and primary pulmonary adenocarcinomas.
M. Foster (2001)
10.1016/S0046-8177(98)90227-1
Value of the MOC-31 monoclonal antibody in differentiating epithelial pleural mesothelioma from lung adenocarcinoma.
N. Ordóñez (1998)
The role of immunohistochemistry in the diagnosis of malignant mesothelioma.
C. Moran (2000)
10.1046/j.1365-2559.2001.01092.x
Immunohistochemistry and the diagnosis of malignant mesothelioma
J. King (2001)
10.1093/AJCP/112.1.75
Role of immunohistochemistry in differentiating epithelial mesothelioma from adenocarcinoma. Review and update.
N. Ordóñez (1999)
10.1111/j.1365-2559.1992.tb00430.x
Intermediate filament expression in mesotheliomas: leiomyoid mesotheliomas are not uncommon
F. Mayall (1992)
10.1016/s0147-0272(88)80005-9
Asbestos-related malignancy.
J. Talcott (1988)
10.1016/0046-8177(93)90080-Z
Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma.
R. Brown (1993)
10.1097/00000478-199612000-00001
Malignant vascular tumors of the serous membranes mimicking mesothelioma. A report of 14 cases.
B. T. Lin (1996)
Keratin protein immunohistochemistry in surgical pathology practice.
Corson Jm (1986)
10.1097/00000478-200009000-00001
The separation of benign and malignant mesothelial proliferations.
A. Churg (2000)
10.1097/00000478-199510000-00003
Localized and diffuse mesotheliomas of the genital tract and peritoneum in women. A clinicopathologic study of nineteen true mesothelial neoplasms, other than adenomatoid tumors, multicystic mesotheliomas, and localized fibrous tumors.
J. Goldblum (1995)
10.1097/00000478-199810000-00006
Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma.
N. Ordóñez (1998)
10.1097/00000478-200101000-00004
Immunohistochemical Panels For Differentiating Epithelial Malignant Mesothelioma From Lung Adenocarcinoma: A Study With Logistic Regression Analysis
R. Carella (2001)
10.1093/AJCP/110.2.191
The diagnosis of desmoplastic malignant mesothelioma and its distinction from fibrous pleurisy: a histologic and immunohistochemical analysis of 31 cases including p53 immunostaining.
W. E. Mangano (1998)
10.1002/(SICI)1096-9896(199704)181:4<362::AID-PATH764>3.0.CO;2-Y
bcl‐2 EXPRESSION IN PLEURAL AND EXTRAPLEURAL SOLITARY FIBROUS TUMOURS
M. Chilosi (1997)
10.1097/00000478-199708000-00008
Thymic carcinomas, but not thymomas and carcinomas of other sites, show CD5 immunoreactivity.
D. Dorfman (1997)
10.1097/00000478-199408000-00008
Expression of CD34 by solitary fibrous tumors of the pleura, mediastinum, and lung.
M. van de Rijn (1994)
Mesothelioma: profile of keratin proteins and carcinoembryonic antigen: an immunoperoxidase study of 20 cases and comparison with pulmonary adenocarcinomas.
J. Corson (1982)
10.1097/00000478-199410000-00003
Solitary Fibrous Tumor Consistent CD34 Immunoreactivity and Occurrence in the Orbit
W. Westra (1994)
10.1038/modpathol.3880175
Cytokeratin 7 and Cytokeratin 20 Expression in Epithelial Neoplasms: A Survey of 435 Cases
P. Chu (2000)
10.1097/00000478-199601000-00004
Biphasic synovial sarcomas arising in the pleural cavity. A clinicopathologic study of five cases.
E. Gaertner (1996)



This paper is referenced by
10.1111/j.1743-7563.2007.00116.x
Management of malignant pleural mesothelioma
A. Nowak (2007)
10.2482/HAIGAN.49.368
Osteopontin modulates malignant pleural mesothelioma cell functions in vitro.
R. Ohashi (2009)
Characterization of Mesothelioma Stem Cells, Their Metabolic Signature and Susceptibility to Selected Mitocans
E. A. Pasdar (2015)
10.1007/978-1-59745-225-0_16
Malignant Peritoneal Mesothelioma
David P. Mangiameli (2007)
10.1043/1543-2165(2005)129[1415:ROHPOD]2.0.CO;2
Recognition of histopathologic patterns of diffuse malignant mesothelioma in differential diagnosis of pleural biopsies.
T. Allen (2005)
10.32964/TJ13.10.49
The potential of fly ash-based calcium silicate as paper filler: Physical properties and printability
Shunxi Song (2014)
10.1016/S1547-4127(04)00113-6
Genetics of malignant pleural mesothelioma: molecular markers and biologic targets.
R. Bueno (2004)
Asbestosis y mesotelioma pleural maligno
Rufino Echegoyen Carmona (2013)
10.1016/S0761-8425(06)72067-8
Formes cliniques des cancers thoraciques: Mésothéliome pleural
P. Astoul (2006)
10.1002/cncr.23034
Accuracy of pleural biopsy using thoracoscopy for the diagnosis of histologic subtype in patients with malignant pleural mesothelioma
L. Greillier (2007)
Tomografía computada de mesotelioma pleural maligno: espectro inusual de imagen
Na Mejía-Duarte (2015)
10.1016/S0169-5002(13)70329-5
110P MALIGNANT PLEURAL MESOTHELIOMA: CLINICOPATHOLOGIC AND SURVIVAL CHARACTERISTICS IN A CONSECUTIVE SERIES OF 40 PATIENTS
R. Bagheri (2013)
10.1016/j.bbrc.2012.02.054
Characterization of cancer stem cell properties of CD24 and CD26-positive human malignant mesothelioma cells.
H. Yamazaki (2012)
10.1002/0471463736.TNMP24.PUB2
Malignant Pleural Mesothelioma
N. Veeramachaneni (2006)
10.15746/SMS.11.036
A Case of Desmoplastic Malignant Mesothelioma
Sang Woo Park (2011)
10.1007/s12032-012-0276-y
Multicentric study on malignant pleural mesothelioma in Turkey: clinicopathologic and survival characteristics of 282 patients
E. T. Elkıran (2012)
10.5124/JKMA.2009.52.5.456
Pathological Diagnosis of Malignant Mesothelioma
Soon Hee Jung (2009)
Mesothelioma of the pericardium in a Bernese mountain dog - a case report.
Katarína Ledecká (2010)
10.1016/j.jtcvs.2009.06.027
Combined treatment with cisplatin and sirolimus to enhance cell death in human mesothelioma.
Mor-Li Hartman (2010)
10.2174/1874467210902020190
Malignant mesothelioma: biology, diagnosis and therapeutic approaches.
M. Tomasetti (2009)
10.1007/978-3-319-26587-2_72-1
Hepatic Mesotheliomas and Related Neoplasms
A. Zimmermann (2016)
10.1016/j.mric.2008.03.004
MR imaging of benign and malignant pleural disease.
R. Gill (2008)
Mesothelioma of the pericardium in a Bernese mountain dog Mesothelioma of the pericardium in a Bernese mountain dog - a case report - a case report
Katarína Ledecká (2010)
10.1097/PAT.0b013e3283445e67
Molecular biomarkers in malignant mesothelioma: state of the art
S. Kao (2011)
10.1517/14728214.12.1.127
Emerging drugs for mesothelioma
G. Scagliotti (2007)
10.7853/KJVS.2015.38.3.199
Malignant mesothelioma of omentum in a dog
Ja-Sil Park (2015)
10.1016/j.athoracsur.2010.04.110
Characteristics of malignant pleural mesothelioma in women.
A. Wolf (2010)
10.1007/978-3-642-10862-4_10
Early stages of mesothelioma, screening and biomarkers.
S. Klebe (2011)
10.1016/J.ATHORACSUR.2004.05.007
Pleural biopsy: a reliable method for determining the diagnosis but not subtype in mesothelioma.
R. Bueno (2004)
10.1016/J.CCM.2006.01.004
Management of malignant pleural mesothelioma.
S. West (2006)
10.1158/0008-5472.CAN-08-1363
Identification of MCAM/CD146 as the target antigen of a human monoclonal antibody that recognizes both epithelioid and sarcomatoid types of mesothelioma.
S. Bidlingmaier (2009)
10.1177/0300891618765538
On the diagnosis of malignant pleural mesothelioma: A necropsy-based study of 171 cases (1997–2016)
P. Barbieri (2018)
See more
Semantic Scholar Logo Some data provided by SemanticScholar